Business profile · Health tech
ArteraAI
Personalized precision medicine powered by AI for cancer therapy
AI-powered digital pathology platform that analyzes patient data to provide personalized cancer treatment recommendations.
About

ArteraAI develops a multimodal AI platform that combines digital pathology analysis with clinical data to personalize cancer treatment. The company offers validated AI-powered tests for prostate cancer and breast cancer that help clinicians predict patient outcomes and treatment response. ArteraAI Prostate Test provides risk stratification for early-stage prostate cancer and metastatic hormone-sensitive prostate cancer, analyzing existing tissue slides without requiring additional staining. The ArteraAI Breast Cancer Test predicts distant metastasis risk and identifies which node-negative patients may benefit from chemotherapy. The platform has received FDA De Novo authorization and is included in the NCCN Clinical Practice Guidelines in Oncology.
Features at a glance
- Analyzes digital pathology with no additional tissue staining required
- Rapid results within 1-2 days after specimen receipt
- Validated across diverse populations including African American and non-African American men
- FDA De Novo authorization for prostate cancer risk stratification
- Insurance coverage for Medicare and many commercial plans
- Provides 5 and 10-year distant metastasis risk for breast cancer
- Identifies breast cancer patients who benefit from chemotherapy
- Included in NCCN Clinical Practice Guidelines for Prostate Cancer
Pricing
Pricing model: Contact for pricing
Compare and explore
Quick answers
- How quickly can ArteraAI test results be obtained?
- Results can be shared within 1-2 days after receipt of the patient's specimen by Artera's CLIA lab.
- Does ArteraAI Prostate Test require additional tissue preparation?
- No. The test analyzes image data from existing H&E slides with no additional staining or tissue preparation required.
- What insurance coverage is available for ArteraAI tests?
- The test is fully reimbursed for Medicare patients and many commercial health plans provide coverage. Financial assistance is available for patients who qualify.
- What is the ArteraAI Breast Cancer Test used for?
- The test provides 5- and 10-year distant metastasis risk estimates for early-stage breast cancer patients and predicts which node-negative patients 50 years or older will benefit from chemotherapy.
- How is ArteraAI Prostate Test validated?
- The test has been validated in dozens of large, randomized phase III clinical trials and shows consistent prognostic performance across diverse populations including African American and non-African American men.
Leave a review for ArteraAI
Reviews of ArteraAI: none yet. Be the first.
Reviews: free. Paid reviews: not possible. See the review file
Reviews and questions · Latest info · Share this info · Your business? Claim this profile · Report outdated info
ArteraAI has a free listing. The owner can unlock the full profile with a paid launch for $5:
- Founder story (locked)
- Milestones (locked)
- Demo video (locked)
- Dofollow website link (locked)
Related profiles
NerveWindow
App that reads your nervous system state and matches it to a short practice to help you regulate and return to focus or rest.
- Health tech
Navina
AI copilot for value-based care that helps clinicians improve HCC accuracy, close care gaps, and reduce documentation burden
- United States
- Health tech
AEONNN
Where longevity becomes intelligence
- United States
- Health tech
CircadiaOS
The thermostat schedule that learns from your sleep
- United States
- Health tech